Cargando…

Underuse of Cardiovascular Medications in Individuals With Known Lower Extremity Peripheral Artery Disease: HCHS/SOL

BACKGROUND: Underuse of cardiovascular medications for secondary prevention among individuals with peripheral artery disease (PAD) has been reported. Little is known about PAD treatment status in the Hispanic/Latino population in the United States, who may have limited access to health care and who...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Simin, Isasi, Carmen R., Kizer, Jorge R., Matsushita, Kunihiro, Allison, Matthew A., Tarraf, Wassim, Qi, Qibin, Ponce, Sonia G., Daviglus, Martha, Kaplan, Robert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660818/
https://www.ncbi.nlm.nih.gov/pubmed/32752978
http://dx.doi.org/10.1161/JAHA.119.015451
_version_ 1783609088948568064
author Hua, Simin
Isasi, Carmen R.
Kizer, Jorge R.
Matsushita, Kunihiro
Allison, Matthew A.
Tarraf, Wassim
Qi, Qibin
Ponce, Sonia G.
Daviglus, Martha
Kaplan, Robert C.
author_facet Hua, Simin
Isasi, Carmen R.
Kizer, Jorge R.
Matsushita, Kunihiro
Allison, Matthew A.
Tarraf, Wassim
Qi, Qibin
Ponce, Sonia G.
Daviglus, Martha
Kaplan, Robert C.
author_sort Hua, Simin
collection PubMed
description BACKGROUND: Underuse of cardiovascular medications for secondary prevention among individuals with peripheral artery disease (PAD) has been reported. Little is known about PAD treatment status in the Hispanic/Latino population in the United States, who may have limited access to health care and who have worse clinical outcomes than non‐Hispanic individuals. METHODS AND RESULTS: We studied the use of cardiovascular therapies in 1244 Hispanic/Latino individuals recruited from 4 sites in the United States, including 826 individuals who reported diagnosis of PAD by physician and 418 individuals with coronary artery disease alone, in the Hispanic Community Health Study/Study of Latinos. We compared the prevalence of using antiplatelet therapy, lipid‐lowering therapy and antihypertensive therapy by PAD and coronary artery disease status. Among those with PAD, we studied factors associated with taking cardiovascular medications, including demographic and socioeconomic factors, acculturation, access to health care and comorbidities, using multivariable regression models. The overall prevalence for individuals with PAD taking antiplatelet therapy, lipid‐lowering therapy and, among hypertensive individuals, antihypertensive therapy was 31%, 26% and 57%, respectively. Individuals of Mexican background had the lowest use for all classes of cardiovascular medications. Older age, number of doctor visits and existing hypertension and diabetes mellitus were significantly associated with taking cardiovascular therapies in adjusted models. Compared with those with PAD alone, individuals with PAD and concurrent coronary artery disease were 1.52 (95% CI, 1.20–1.93) and 1.74 (1.30–2.32) times more likely to use antiplatelet agents and statins according to multivariable analysis. No significant difference of antihypertensive medication use was found among PAD patients with or without coronary artery disease. CONCLUSIONS: Hispanic/Latino individuals with known PAD underuse cardiovascular medications recommended in clinical guidelines. More efforts should be directed to improve treatment in this important group.
format Online
Article
Text
id pubmed-7660818
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76608182020-11-17 Underuse of Cardiovascular Medications in Individuals With Known Lower Extremity Peripheral Artery Disease: HCHS/SOL Hua, Simin Isasi, Carmen R. Kizer, Jorge R. Matsushita, Kunihiro Allison, Matthew A. Tarraf, Wassim Qi, Qibin Ponce, Sonia G. Daviglus, Martha Kaplan, Robert C. J Am Heart Assoc Original Research BACKGROUND: Underuse of cardiovascular medications for secondary prevention among individuals with peripheral artery disease (PAD) has been reported. Little is known about PAD treatment status in the Hispanic/Latino population in the United States, who may have limited access to health care and who have worse clinical outcomes than non‐Hispanic individuals. METHODS AND RESULTS: We studied the use of cardiovascular therapies in 1244 Hispanic/Latino individuals recruited from 4 sites in the United States, including 826 individuals who reported diagnosis of PAD by physician and 418 individuals with coronary artery disease alone, in the Hispanic Community Health Study/Study of Latinos. We compared the prevalence of using antiplatelet therapy, lipid‐lowering therapy and antihypertensive therapy by PAD and coronary artery disease status. Among those with PAD, we studied factors associated with taking cardiovascular medications, including demographic and socioeconomic factors, acculturation, access to health care and comorbidities, using multivariable regression models. The overall prevalence for individuals with PAD taking antiplatelet therapy, lipid‐lowering therapy and, among hypertensive individuals, antihypertensive therapy was 31%, 26% and 57%, respectively. Individuals of Mexican background had the lowest use for all classes of cardiovascular medications. Older age, number of doctor visits and existing hypertension and diabetes mellitus were significantly associated with taking cardiovascular therapies in adjusted models. Compared with those with PAD alone, individuals with PAD and concurrent coronary artery disease were 1.52 (95% CI, 1.20–1.93) and 1.74 (1.30–2.32) times more likely to use antiplatelet agents and statins according to multivariable analysis. No significant difference of antihypertensive medication use was found among PAD patients with or without coronary artery disease. CONCLUSIONS: Hispanic/Latino individuals with known PAD underuse cardiovascular medications recommended in clinical guidelines. More efforts should be directed to improve treatment in this important group. John Wiley and Sons Inc. 2020-08-05 /pmc/articles/PMC7660818/ /pubmed/32752978 http://dx.doi.org/10.1161/JAHA.119.015451 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Hua, Simin
Isasi, Carmen R.
Kizer, Jorge R.
Matsushita, Kunihiro
Allison, Matthew A.
Tarraf, Wassim
Qi, Qibin
Ponce, Sonia G.
Daviglus, Martha
Kaplan, Robert C.
Underuse of Cardiovascular Medications in Individuals With Known Lower Extremity Peripheral Artery Disease: HCHS/SOL
title Underuse of Cardiovascular Medications in Individuals With Known Lower Extremity Peripheral Artery Disease: HCHS/SOL
title_full Underuse of Cardiovascular Medications in Individuals With Known Lower Extremity Peripheral Artery Disease: HCHS/SOL
title_fullStr Underuse of Cardiovascular Medications in Individuals With Known Lower Extremity Peripheral Artery Disease: HCHS/SOL
title_full_unstemmed Underuse of Cardiovascular Medications in Individuals With Known Lower Extremity Peripheral Artery Disease: HCHS/SOL
title_short Underuse of Cardiovascular Medications in Individuals With Known Lower Extremity Peripheral Artery Disease: HCHS/SOL
title_sort underuse of cardiovascular medications in individuals with known lower extremity peripheral artery disease: hchs/sol
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660818/
https://www.ncbi.nlm.nih.gov/pubmed/32752978
http://dx.doi.org/10.1161/JAHA.119.015451
work_keys_str_mv AT huasimin underuseofcardiovascularmedicationsinindividualswithknownlowerextremityperipheralarterydiseasehchssol
AT isasicarmenr underuseofcardiovascularmedicationsinindividualswithknownlowerextremityperipheralarterydiseasehchssol
AT kizerjorger underuseofcardiovascularmedicationsinindividualswithknownlowerextremityperipheralarterydiseasehchssol
AT matsushitakunihiro underuseofcardiovascularmedicationsinindividualswithknownlowerextremityperipheralarterydiseasehchssol
AT allisonmatthewa underuseofcardiovascularmedicationsinindividualswithknownlowerextremityperipheralarterydiseasehchssol
AT tarrafwassim underuseofcardiovascularmedicationsinindividualswithknownlowerextremityperipheralarterydiseasehchssol
AT qiqibin underuseofcardiovascularmedicationsinindividualswithknownlowerextremityperipheralarterydiseasehchssol
AT poncesoniag underuseofcardiovascularmedicationsinindividualswithknownlowerextremityperipheralarterydiseasehchssol
AT daviglusmartha underuseofcardiovascularmedicationsinindividualswithknownlowerextremityperipheralarterydiseasehchssol
AT kaplanrobertc underuseofcardiovascularmedicationsinindividualswithknownlowerextremityperipheralarterydiseasehchssol